Arena Pharmaceuticals — Shareholder Meeting (June 2016)
7 slides from Arena Pharmaceuticals's shareholder meeting presentation, Jun 10, 2016
Slide 1: June 2016 Annual Meeting
J u n e 2 0 1 6 Annual Meeting
Slide 2: Forward Looking Statement
Forward Looking Statement 2 This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about our and others’ focus, mission, goals, strategy, approach, plans, timelines, milestones and expectations; R&D programs and BELVIQ, including
Slide 3: Corporate Priorities: Advance Novel Clinical Programs
Corporate Priorities 3 Etrasimod (APD334) in ulcerative colitis (P2 ongoing) Ralinepag (APD811) in pulmonary arterial hypertension (P2 ongoing) APD371 in pain indications (P2 ready) Evaluate expansion into other indications Advance Novel Clinical Programs 1
Slide 4: Corporate Priorities: Streamline Operations
Corporate Priorities (continued) Etrasimod (APD334) in ulcerative colitis (P2 ongoing) Ralinepag (APD811) in pulmonary arterial hypertension (P2 ongoing) APD371 in pain indications (P2 ready) Evaluate expansion into other indications Advance the Novel Clinical Programs 1 Define and focus o
Slide 5: Corporate Priorities: Support Collaborations
Corporate Priorities (continued) 5 Etrasimod (APD334) in ulcerative colitis (P2 ongoing) Ralinepag (APD811) in pulmonary arterial hypertension (P2 ongoing) APD371 in pain indications (P2 ready) Evaluate expansion into other indications Advance the Novel Clinical Programs 1 Define and focus
Slide 6: Pipeline
6 Program Indication Pre- Clinical Phase 1 Phase 2 Phase 3 Post Market Commercial Rights Internal Programs Etrasimod (APD334) S1P1 Modulator Ulcerative Colitis Arena: Worldwide Ralinepag (APD811) PGI2 Agonist PAH APD371 CB2 Agonist Pain Partnered Programs BELVIQ (CVOT Study) CV Outcomes, T2D Convers
Slide 7: Thank You
Thank You 7
Arena Pharmaceuticals — Shareholder Meeting (June 2016) on 6ix